



Antioxidative and aldose reductase-inhibitory effects of a fermentation filtrate of *Rubus coreanus*

Sang-Chul Kwon¹, Yun-Bae Kim^{2*}

¹Food Safety Support Organization, Korea Food Industry Association, Seoul, Korea

²College of Veterinary Medicine, Chungbuk National University, Cheongju, Korea

Antioxidative and aldose reductase (AR)-inhibitory effects of a fermentation filtrate of *Rubus coreanus* (FRC) were investigated using corneal/retinal homogenate and lens cytosol, respectively. Rat corneal/retinal homogenate was treated with 50 μ M FeCl₃ in the presence of FRC (3.2-100 μ g/mL) for 30 min at 37°C, and thiobarbituric acid-reactive substances (TBARS) was quantified as a lipid peroxidation parameter. FRC markedly suppressed the TBARS production in a concentration-dependent manner, leading to 50% (IC₅₀) and 100% (IC₁₀₀) inhibitory concentrations of 20 and 95 μ g/mL, respectively, which was similar to the effect of butylated hydroxyanisole. Activity of AR from rat lens was assayed in the presence of FRC (1-31.6 μ g/mL) at 25°C using glyceraldehyde as a substrate. FRC inhibited lens AR by 50% (IC₅₀) and 90% (IC₉₀) at approximately 2 and 31.6 μ g/mL, respectively, comparable to the effect of quercetin. The results indicate that FRC could be a promising candidate for the improvement of eye injury and visual dysfunction of dry eye and diabetic patients.

Key words: *Rubus coreanus*, antioxidative activity, aldose reductase inhibition

Received 3 October 2011; Revised version received 10 October 2011; Accepted 10 October 2011

Dry eye comes from injuries of lacrimal functional unit (lacrimal glands, cornea and eyelids and/or impairments of sensory and motor nerves connecting the unit lacrimal functional unit [1]. The disease is a complex symptom with rapid breakdown of tear film, resulting in corneal damage hindering eye ball movement and convenient seeing [2-4]. The major causes of dry eye are 1) environmental factors such as reduced blinking frequency, aging, low humidity, and antimuscarinic agents including atropine, 2) secondary effect from immune dysfunction in Sjogren syndrome (or sicca syndrome) and rheumatoid arthritis, and 3) excessive evaporation of tears [5-8].

Diabetic retinopathy (DR), one of the most serious complications of diabetes mellitus, frequently leads to blindness [9,10]. Proliferative diabetic retinopathy (PDR) is the advanced stage of DR characterized by new vessel formation accompanied by fibrous tissue accumulation leading to vitreous hemorrhage and subsequent tractional retinal detachment.

Among several biochemical changes, increased oxidative stress [11-13] and accumulation of advanced glycation end products (AGE) [14,15] may underlie the development of PDR. Since excess accumulation of sorbitol produced from high glucose by the catalytic activity of aldose reductase (AR) also contribute to DR, some new drugs targeting these biochemical changes, such as antioxidants [11-13], aldose reductase inhibitors [16] and AGE inhibitors [17,18], have been studied as candidates for the prevention of corneal injury and improvement of AR.

Rubus coreanus, which is well known as its Korean name “Bokbunja”, has antiinflammatory, antifatigue, antioxidative and male reproductive function-recovering properties [19-22]. Since focal blood flow is one of the key factors of diabetic foot ulcers [23], it is suggested that vasodilatating polyphenols in *Rubus coreanus*, ginsenosides and vitamin C should be beneficial for the improvement of visual function [22,24,25]. It is of interest to note that they are also strong antioxidants [21,26], and especially ginseng components and vitamin C

*Corresponding author: Yun-Bae Kim, College of Veterinary Medicine and Research Institute of Veterinary Medicine, Chungbuk National University, 52 Naesudongro (Gaesin-dong), Cheongju, Chungbuk 361-763, Korea
Tel: +82-43-261-3358; FAX: +82-43-271-3246; E-mail: solar93@cbu.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

were found to inhibit AR [27,28]. Such results led us to investigate the antioxidative and AR-inhibitory activities of a fermentation filtrate of *Rubus coreanus* (FRC) in the eye tissues, to confirm its potential effectiveness for the improvement of visual function.

Ripe (reddish purple) fruits of the *Rubus coreanus* plant were purchased from an organic farm at Hamyang, Korea, in 2008. The fruits were minced, macerated, and adjusted to 25-30% precipitates by adding purified water, to produce a 20% starch content mixture. Into the homogenate, cultivated *Saccharomyces* (strain HM 2104) was added up to 4% and fermented at 45°C and pH 5.5 for 30-40 h. The crude culture precipitates were removed by centrifugation and microfiltration (pore size, 0.05 µm), and the alcohol produced during fermentation was fully removed in a vacuum evaporator.

Cornea and retina were obtained from the eye balls of Sprague-Dawley (SD) rats by removing the lens and vitreous body on an ice block. The tissues were homogenized in 19 volumes of 10 mM sodium phosphate-buffered saline (PBS, pH7.4) to make a 5% homogenate at 4°C. To induce lipid peroxidation, the homogenate (225 µL) was mixed with 12.5 µL ferric chloride (FeCl₃, final 50 µM) in the presence of FRC (final 3.2-100 µg/mL) or butylated hydroxyanisole (BHA, final 100 µM), and incubated for 30 min at 37°C. The reaction was then stopped by adding 250 µL sodium dodecyl sulphate (SDS, 8.1% solution) and 500 µL 20% acetic acid (adjusted to pH 3.5). After adding 250 µL 2-thiobarbituric acid (TBA, 0.75% solution), the mixture was boiled in a glass tube capped with aluminum foil for 30 min. Samples were cooled on ice, centrifuged at 13,000 g for 10 min, and absorbance of the supernatant was read at 532 nm for the quantification of thiobarbituric acid-reactive substances (TBARS).

Lenses of SD rats were vigorously homogenized in 9 volumes of homogenization buffer (100 mM sodium phosphate, 0.5 mM phenylmethylsulfonylfluoride, 10 mM 2-mercaptoethanol, pH7.0) to make a 5% homogenate at 4°C. The homogenate was centrifuged at 105,000 g for 60 min, and the supernatant (cytosol) was used as AR enzyme source. Into 417.5 µL sodium phosphate buffer (100 mM, pH7.0), 50 µL lens cytosol), 10 µL β-nicotinamide adenine dinucleotide phosphate (reduced form of NADPH, final 0.16 mM) and FRC (final 1-31.6 µg/mL), vitamin C (final 10-100 µg/mL) or quercetin (final 0.32-31.6 µg/mL) were added, and mixed well. After adding 12.5 µL glyceraldehyde (10 mM in 2% NaCO₃ in 0.1 N NaOH, pH 7.0), absorbance change at 340 nm was recorded for 5 min at 25°C.

Data were expressed as the mean±SEM. Statistical analysis was performed using an analysis of variance (ANOVA) with the aid of SPSS for Windows v.10.0 (Chicago, Illinois, USA).

Table 1. Antioxidative effects of a fermentation filtrate of *Rubus coreanus* (FRC) and butylated hydroxyanisole (BHA) on FeCl₃-induced lipid peroxidation of cornea and retina

Treatment	Concentration (µg/mL)	TBARS (nM)	% of control
Vehicle	-	1.58±0.92	100.0±7.7
FeCl ₃ alone	(50 µM)	2.76±0.87	174.7±9.2*
	3.2	2.55±0.60	161.4±5.5
	10	2.28±0.57	144.3±8.2#
	31.6	1.97±0.54	124.7±5.8#
	100	1.54±0.47	97.5±5.4#
BHA	100	1.61±0.41	101.9±6.4#

TBARS: thiobarbituric acid-reactive substances. *Significantly different from vehicle control ($P<0.05$). #Significantly different from FeCl₃ alone ($P<0.05$).

A P value <0.05 was considered statistically significant.

Fifty µM FeCl₃ significantly increased TBARS concentration, lipid peroxidation products, by 74.7% (Table 1). Oxidative stress is an important factor for damage of eye components including cornea and retina in dry eye and diabetic patients [4,12]. However, FRC treatment markedly attenuated the TBARS production in a concentration-dependent manner (40.7% at 10 µg/mL and 66.9% at 31.6 µg/mL), leading to 50% (IC₅₀) and 100% (IC₁₀₀) inhibitory concentrations of 20 µg/mL and 95 µg/mL, respectively, which was comparable to the effect of a well-known antioxidant BHA. In fact, antioxidative activities of *Rubus coreanus* and its ingredients has been reported in other oxidation-inducing systems (lipopolysaccharide or copper) in different tissues (liver and lipoproteins) [21,26]. Notably, therefore, it was confirmed that *Rubus coreanus* exerts antioxidative activity in diverse oxidative systems including hepatic inflammation, atherosclerosis and ocular injury.

FRC remarkably inhibited lens AR in a concentration-dependent manner (37.4 and 67.7% at 1 and at 3.16 µg/mL), leading to IC₅₀ and IC₉₀ of 2 and 31.6 µg/mL, respectively (Table 2). Notably, vitamin C did not significantly inhibit lens AR activity, in contrast to the strong inhibition of erythrocyte AR [28]. Such a discrepancy in the inhibition of AR might be due to the differences in tissues, implying that vitamin C can exert negligible inhibitory effect on AR in the target tissue (lens), rather than in blood erythrocytes with limited access to eye tissues. In contrast, quercetin strongly inhibited AR activity, leading to 50 and 90% inhibition at 0.4 and 20 µg/mL, respectively. The AR-inhibitory activity of quercetin was higher than FRC. Unfortunately, however, it was reported that quercetin has genotoxicity [29], implying that safety assessment on quercetin is required for human trials. By comparison, *Rubus coreanus* is being widely consumed as diverse types of wine or juice in Korea. Although ginseng

Table 2. Inhibitory effects of a fermentation filtrate of *Rubus coreanus* (FRC), vitamin C and quercetin on lens aldose reductase

Treatment	Concentration (μg/mL)	ΔOD/min	% of control
Vehicle	-	0.0215±0.0028	100.0±11.8
FRC	1	0.0134±0.0021	62.3±6.6*
	3.2	0.0076±0.0033	35.3±10.1*
	10	0.0045±0.0011	20.9±4.1*
	31.6	0.0023±0.0008	10.7±4.6*
	100	0.0230±0.0031	107.0±13.2
Vitamin C	31.6	0.0223±0.0033	103.7±12.7
	100	0.0204±0.0021	94.9±5.3
	1000	0.0204±0.0021	94.9±5.3
Quercetin	0.32	0.0112±0.0019	52.1±8.8*
	1	0.0057±0.0018	26.5±6.4*
	3.2	0.0046±0.0024	21.4±7.0*
	10	0.0030±0.0011	14.0±2.8*
	31.6	0.0015±0.0005	7.0±1.6*

TBARS: thiobarbituric acid-reactive substances. *Significantly different from vehicle control ($P<0.05$).

was demonstrated to inhibit lens AR [27], FRC was superior to ginseng extract in our study (data not shown).

Taken together, our results demonstrated that FRC exhibits strong antioxidative and AR-inhibitory activities in eye components, in addition to its vasodilatating effect. Although the analysis of active ingredients remains to be clarified, it is suggested that FRC could be a promising candidate for the improvement of eye injury and visual dysfunction of dry eye and diabetic patients.

Acknowledgment

This work was supported by Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0094035).

References

- Nakamura S, Shibuya M, Nakashima H, Imagawa T, Uehara M, Tsubota K. D-β-Hydroxybutyrate protects against corneal epithelial disorders in a rat dry eye model with jogging board. *Invest Ophthalmol Vis Sci* 2005; 46: 2379-2387.
- Holly FJ, Lemp MA. Tear physiology and dry eyes. *Surv Ophthalmol* 1977; 22: 69-87.
- Tseng SC, Tsubota K. Important concepts for treating ocular surface and tear disorders. *Am J Ophthalmol* 1997; 124: 825-835.
- Nakamura S, Shibuya M, Nakashima H, Hisamura R, Masuda N, Imagawa T, Uehara M, Tsubota K. Involvement of oxidative stress on corneal epithelial alterations in a blink-suppressed dry eye. *Invest Ophthalmol Vis Sci* 2007; 48: 1552-1558.
- Tsubota K, Nakamori K. Dry eyes and video display terminals. *N Engl J Med* 1993; 328: 584.
- Tsubota K, Toda I, Nakamori K. Poor illumination, VDTs, and desiccated eyes. *Lancet* 1996; 347: 768-769.
- Wolkoff P, Nøjgaard JK, Troiano P, Piccoli B. Eye complaints in the office environment: precorneal tear film integrity influenced by eye blinking efficiency. *Occup Environ Med* 2005; 62: 4-12.
- Diagnostic Subcommittee of the International Dry Eye. Methodologies to diagnose and monitor dry eye. *Ocul Surf* 2007; 5: 108-152.
- Hyman L. Epidemiology of eye disease in the elderly. *Eye* 1987; 1: 330-341.
- Klein BE, Klein R. Ocular problems in older Americans with diabetes. *Clin Geriatr Med* 1990; 6: 827-837.
- Hammes HP, Brownlee M, Lin J, Schleicher E, Bretzel RG. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product N-epsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations. *Diabetologia* 1999; 42: 603-607.
- Altomare E, Grattagliano I, Vendemaile G, Micelli-Ferrari T, Signorile A, Cardia L. Oxidative protein damage in human diabetic eye: evidence of a retinal participation. *Eur J Clin Invest* 1997; 27: 141-147.
- Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, Kim RY, Rohan RM, Colby KA, Yeo KT, Adamis AP. Reactive oxygen intermediates increase vascular endothelial growth factor expression *in vitro* and *in vivo*. *J Clin Invest* 1996; 98: 1667-1675.
- Murata T, Nagai R, Ishibashi T, Inomata H, Ikeda K, Horiuchi S. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. *Diabetologia* 1997; 40: 764-769.
- Hammes HP, Wellensiek B, Klöting I, Sickel E, Bretzel RG, Brownlee M. The relationship of glycaemic level to advanced glycation end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster. *Diabetologia* 1998; 41: 165-170.
- Robinson WG, Nagata M, Laver N, Kinoshita JH. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. *Invest Ophthalmol Vis Sci* 1989; 30: 2285-2292.
- Hammes HP, Strodtter D, Weiss A, Bretzel RG, Federlin K, Brownlee M. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. *Diabetologia* 1995; 38: 656-660.
- Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits development of experimental diabetic retinopathy. *Proc Natl Acad Sci USA* 1991; 88: 11555-11558.
- Choi JW, Lee KT, Ha JH, Yun SY, Ko CD, Jung HJ, Park HJ. Antinociceptive and antiinflammatory effects of nigicichigoside F1 and 23-hydroxytormentic acid obtained from *Rubus coreanus*. *Biol Pharm Bull* 2003; 26: 1436-1441.
- Jung KA, Han D, Kwon EK, Lee CH, Kim YE. Antifatigue effect of *Rubus coreanus* Miquel extract in mice. *J Med Food* 2007; 10, 689-693.
- Kim ID, Kang KS, Kwon RH, Ha BJ. Anti-oxidative effects of *Rubus coreanus* Miquel extract on hepatic injury induced by lipopolysaccharide. *J Toxicol Pub Health* 2007; 23, 347-352.
- Jeon JH, Shin S, Park D, Jang JY, Choi B, Kang JK, Joo SS, Hwang SY, Kim JC, Kim YB. Fermentation filtrates of *Rubus coreanus* relax the corpus cavernosum, and increase sperm count and motility. *J Med Food* 2008; 11, 474-478.
- Cicco G, Giorgino F, Cicco S. Wound healing in diabetes: hemorheological and microcirculatory aspects. *Adv Exp Med Biol*. 2011; 701: 263-269.
- Matsumoto H, Nakamura Y, Tachibanaki S, Kawamura S, Hirayama M. Stimulatory effect of cyanidin 3-glycosides on the regeneration of rhodopsin. *J Agric Food Chem* 2003; 51:

3560-3563.

25. Wang X, Chu S, Qian T, Chen J, Zhang J. Ginsenoside Rg1 improves male copulatory behavior via nitric oxide/cyclic guanosine monophosphate pathway. *J Sex Med* 2010; 7: 743-750.

26. Yeomans VC, Linseisen J, Wolfram G. Interactive effect of polyphenols, tocopherol and ascorbic acid on the Cu⁺⁺-mediated oxidative modification of human low density lipoproteins. *Eur J Nutr* 2005; 44: 422-428.

27. Kim HS, Park WY, Seong YH. Inhibitory effects of ginseng components on rat lens aldose reductase activities. *J Ginseng Res* 1996; 20: 106-110.

28. Vincent TE, Mendiratta S, May JM. Inhibition of aldose reductase in human erythrocytes by vitamin C. *Diabetes Res Clin Pract* 1999; 43: 1-8.

29. Stopper H, Schmitt E, Kobras K. Genotoxicity of phytoestrogens. *Mutat Res* 2005; 574: 139-155.